Loading the content... Loading depends on your connection speed!

Shopping Cart - $0.00

Central Nervous System Drugs Market Global Briefing 2017

Central Nervous System Drugs Market Global Briefing 2017

From $1,000.00

Including: Anaesthetics, Analgesics, Anti-Parkinson drugs, Anti-Epileptics, Other CNS drugs.
Covering: Biogen Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Pfizer Inc., Novartis AG, Shire Plc., UCB S.A., Eli Lilly And Company, Sanofi S.A., Daiichi Sankyo Company, Limited


Clear selection
SKU: 2272. Categories: , .
Description

The USA was the largest country in the central nervous system drugs market in 2016, accounting for around 28% market share. This can be attributed to high drug prices and increased healthcare spending in the USA compared to other countries. It is followed by Germany and Brazil with around 4% and 3.5% share of the market.

Central Nervous System Drugs Market Global Briefing from the Business Research Company covers market characteristics, size and growth, segmentation, regional breakdowns, competitive landscape, market shares, trends and strategies for this market.

The market characteristics section of the report defines and explains the market.

The market size section gives the central nervous system drugs market revenues, covering both the historic growth of the market and forecasting the future.

Drivers and restraints looks at the external factors supporting and controlling the growth of the market.

Market segmentations break down the key sub sectors which make up the market. The regional breakdowns section gives the size of the market geographically.

Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in the last three years are identified.

The trends and strategies section highlights the likely future developments in the central nervous system drugs market and suggests approaches.

Reasons to Purchase

• Get up to date information available on the central nervous system drugs market globally.
• Identify growth segments and opportunities.
• Facilitate decision making on the basis of historic and forecast data and understand the drivers and restraints on the market.
• Develop strategies based on likely future developments.
• Gain a global perspective on the development of the market.

 

Scope

Markets Covered: Anaesthetics, Analgesics, Anti-Parkinson drugs, Anti-Epileptics, Other CNS drugs.
Companies Mentioned: Biogen Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Pfizer Inc., Novartis AG, Shire Plc., UCB S.A., Eli Lilly And Company, Sanofi S.A., Daiichi Sankyo Company Limited
Geographic scope: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa
Time series: Five years historic and forecast.
Data: Market value in $ billions.
Data segmentations: Regional breakdowns, market share of competitors, key sub segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Executive Summary
The central nervous system drugs market includes medications that are used in the treatment of diseases affecting the brain or spinal cord. The central nervous system (CNS) integrates sensory information and instructs the body to respond accordingly. The spinal cord is a channel for signals between the brain and the rest of the body. Central nervous system (CNS) disorder is a condition in which the brain and spinal cord’s ability to function is affected, hence affecting the body.

The global central nervous system drugs market is expected to reach around $82 billion in 2020. Going forward, the growth of this market can be attributed to steps taken by the US FDA (Food and Drug Administration) and EMA (European Medicines Agency) to offer allotment of special regulatory designations for Central Nervous System disorders which will help in the faster entry of drugs into the market for treatment of serious nervous system related conditions.

Wearables To Improve R&D - Pharmaceutical companies are partnering with technology companies and incorporating wearables in clinical studies and for research and development of CNS disease treatments. These wearable devices make use of sensors to detect early symptoms of Parkinson’s disease such as tremors, slowness and stiffness in patients. Researchers use this data to gain insights about the disease and potential drug reactions, and thus reduce the time for trials by 30% to 50%. For instance, in 2016, Michael J. Fox Foundation for Parkinson’s Research collaborated with specialty drugmaker Cynapsus Therapeutics and Intel to integrate wearable technology in a Phase-III clinical trial of APL-130277, an experimental drug for Parkinson’s disease. Biogen, a leading CNS drugmaker is using Fitbit, a smart wearable tracker, to better understand multiple sclerosis in patient studies, and the technology is expected to extend in Alzheimer’s disease research.
Table of Contents
Central Nervous System Drugs Market Characteristics 5
Central Nervous System Drugs Market Historic Growth 7
Central Nervous System Drugs Market Forecast Growth 9
Central Nervous System Drugs Market Segmentation 11
Global Central Nervous System Drugs Market, Split By Segments, 2016, $ Billion 11
Anaesthetics 12
Analgesics 12
Anti-Parkinson drugs 12
Anti-Epileptics 12
Other CNS drugs 12
Global Central Nervous System Drugs Market, Historic and Forecast, Split By Segments, 2012-2020 13
Central Nervous System Drugs Market Geography Regional and Country Comparison 15
Global Central Nervous System Drugs Market, Split By Regions, 2016 15
Global Central Nervous System Drugs Market, Historic And Forecast Growth Rate, Split By Region, 2012-2020 17
Global Central Nervous System Drugs Market, Split By Country, 2016 19
Global Central Nervous System Drugs Market, Historic And Forecast Growth Rate, Split By Country, 2012-2020 21
Central Nervous System Drugs Market Competitive Landscape 23
Biogen Inc. 24
F. Hoffmann-La Roche Ltd. 24
Johnson & Johnson 24
Pfizer Inc. 24
Novartis AG 24
Shire Plc. 24
Eli Lilly And Company 24
UCB S.A. 24
Daiichi Sankyo Company, Limited 24
Sanofi S.A. 24
Biogen Idec 25
F.Hoffmann-La Roche 25
Johnson & Johnson (J&J) 26
Central Nervous System Drugs Market Key Mergers And Acquisitions 27
Teva Acquired Auspex Pharmaceuticals 27
Pfizer Acquired Bamboo Therapeutics 27
Sunovion Acquired Cynapsus Therapeutics 27
Novartis Acquired Spinifex Pharmaceuticals 27
Otsuka Acquired Neurovance 27
Biogen Acquired Rodin Therapeutics 28
Central Nervous System Drugs Market Trends And Strategies 29
Wearables To Improve R&D 29
Biomarkers In CNS Drug Development 29
Regenerative Therapies For Central Nervous System Diseases 29
Appendix 31
NAICS Definitions Of Industry Covered In This Report 31
Definition Of Market Covered In This Report 31
Abbreviations 31
Currencies 31
Research Methodology 32
Research Inquiries 33
The Business Research Company 33

List of Figures
Figure 1: Global Central Nervous System Drugs Market, Historic Market Size, 2012-2016, $ Billion 7
Figure 2: Global Central Nervous System Drugs Market, Forecast Market Size, 2016 – 2020, $ Billion 9
Figure 3: Global Central Nervous System Drugs Market, Split By Segments, 2016, $ Billion 11
Figure 4: Global Central Nervous System Drugs Market, Historic and Forecast, Split By Segment, 2012 – 2020 13
Figure 5: Global Central Nervous System Drugs Market, Split By Region, 2016, $ Billion 15
Figure 6: Global Central Nervous System Drugs Market, Historic And Forecast Growth Rate, Split By Region, 2012-2020 17
Figure 7: Global Central Nervous System Drugs Market, Split By Country, 2016, $ Billion 19
Figure 8: Global Central Nervous System Drugs Market, Historic And Forecast Growth Rate, Split By Country, 2012-2020 21
Figure 9: Global Central Nervous System Drugs Market, Key Competitor Market Shares, 2016, Percentage (%) 23

List of Tables
Table 1: Global Central Nervous System Drugs Market, Historic Market Size, 2012-2016, $ Billion 7
Table 2: Global Central Nervous System Drugs Market, Forecast Market Size, 2016 – 2020, $ Billion 9
Table 3: Global Central Nervous System Drugs Market, Split By Segments, 2016, $ Billion 11
Table 4: Global Central Nervous System Drugs Market, Historic and Forecast, Split By Segment, 2012 – 2020 13
Table 5: Global Central Nervous System Drugs Market, Split By Region, 2016, $ Billion 16
Table 6: Global Central Nervous System Drugs Market, Historic And Forecast Growth Rate, Split By Region, 2012-2020 17
Table 7: Global Central Nervous System Drugs Market, Split By Country, 2016, $ Billion 19
Table 8: Global Central Nervous System Drugs Market, Historic And Forecast Growth Rate, Split By Country, 2012-2020 21
Table 9: Global Central Nervous System Drugs Market, Key Competitor Market Shares, 2016, Percentage (%) 24
Get Customized Report
Please fill in your details. Our team will get back to you